Haematologic Technologies, Inc.

57 River Road

Essex Junction, VT USA

Tel: 802.878.1777

Fax: 802.878.1776

Email: hti@haemtech.com

HOME PAGE

 

Fluorogenic Substrates for Coagulation Enzymes

GENERAL STRUCTURE OF ANSN-BASED FLUOROGENIC SUBSTRATES The general structure of 6-amino-1-naphthalenesulfonamide-based (ANSN) fluorogenic substrates is illustrated. In the present family of compounds, R1 is a tripeptide of which the COOH-terminal residue is typically an arginine. R2 and R3 may be either a hydrogen, alkyl, aryl, or cycloalkyl group. The dotted line indicates the site of hydrolysis by the various serine proteases.

 

Substrates containing the fluorescent reporter group 6-amino-1-naphthalene-sulfonamide (ANSN) are useful compounds for monitoring the enzyme activity of various serine proteases (1-12). In this class of compounds, the ANSN reporter group is linked (in the R1 position) to short tri-peptide sequences. The peptide sequences are designed to optimize the interaction between the enzyme and substrate. Additional components which may be added to the R2 and R3 positions reflect changes in the P' subsite positions, and generally affect the kinetic parameters of the substrates. Compounds which are effective substrates are hydrolyzed between the tri-peptide and the ANSN group. Once cleaved from the peptide moiety, the ANSN group exhibits about a 1000 fold increase in relative fluorescence. 


The kinetic properties identified on the following page will aid in the selection of an appropriate substrate. The ANSN substrates have proved especially useful for the analyses of factor VIIa (1-5,7,9,10,12). Although the substrate hydrolysis rates are relatively slow for factor VIIa alone, several compounds such as compound SN-17a exhibit a large change in kcat when tissue factor is incorporated into the assay system. 

The ANSN-based substrates are provided as 10mM stock solutions in DMSO. Assays are typically conducted in physiologic buffers containing Hepes or Tris, with substrate concentrations ranging from 1 to 100 µM. The relative change in fluorescence is monitored at a 470 nm emission wavelength with a 352 nm excitation wavelength. Light artifacts can be minimized by employing a 390 to 450 nm long-pass cutoff filter in the emission beam. 

The stock substrate solutions in DMSO should be stored frozen at 4°C or colder, and should be protected from light. Under these conditions the compounds will remain stable for over one year. 

 

 

 ANSN - BASED - FLUOROGENIC SUBSTRATES

 

CAT.#

STRUCTURE

KINETIC PROPERTIES
(KM - µM; kcat - s-1; kcat/KM - M-1s-1x10-5)

PRICING

IIa VIIa VIIa/TF Xa XIa aPC tPA Plasmin
SN-5 D-AFK-ANSNH-iC4H9.2HBr
F.W. = 786.6
(useful for plasmin)
KM
kcat
kcat/KM
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
130
3.7
0.28
SN-7 Mes-D-LGR-ANSN(C2H5)2
F.W. = 682.8
(useful for factor Xa)
KM
kcat
kcat/KM
31
0.63
0.2
180
0.007
0.0004
200
0.79
0.04
125
36
2.9
580
15
0.26
113
0.055
0.005
ND
ND
ND
ND
ND
ND
SN-13a D-LPR-ANSNH-C3H7 • 2 HCl
F.W. = 721.74
(useful for factor XIa)
KM
kcat
kcat/KM
0.5
19
380
300
0.07
0.002
300
4.5
0.15
171
3.3
0.19
75
53
7.1
45
52
12
98
0.31
0.03
ND
ND
ND
SN-17a D-FPR-ANSNH-C6H11 • 2 HCl
F.W. = 777.81
(useful for IIa & factor VIIa)
KM
kcat
kcat/KM
0.4
17
430
150
0.05
0.004
330
8.4
0.25
150
0.32
0.02
ND
ND
ND
7.8
6.6
8.6
36
0.074
0.02
ND
ND
ND
SN-17c D-FPR-ANSNH-C4H9 • 2 HCl
F.W. = 751.76
(useful for factor VIIa)
KM
kcat
kcat/KM
ND
ND
ND
186
0.11
0.006
102
2.7
0.26
ND
ND
ND
ND
ND
ND
53
21
4.0
ND
ND
ND
ND
ND
ND
SN-18 Boc-L-(p-F)FPR-ANSNH-C2H5
F.W. = 768.92
(useful for tPA)
KM
kcat
kcat/KM
3.7
44
120
50
0.008
0.002
217
0.88
0.04
ND
ND
ND
ND
ND
ND
ND
ND
ND
71
1.03
0.15
ND
ND
ND
SN-20 Boc-L-FPR-ANSNH-C2H5
F.W. = 750.90
(useful for thrombin)
KM
kcat
kcat/KM
17.0
58
34
ND
ND
ND
ND
ND
ND
100
0.31
0.003
ND
ND
ND
540
2.2
0.04
47
0.011
0.002
ND
ND
ND
SN-45 L-EGR-ANSNH-C3H7 • 2 HBr
F.W. = 724.6
(useful for factor XIa)
KM
kcat
kcat/KM
100
2.5
0.25
ND
ND
ND
ND
ND
ND
110
0.20
0.02
225
82
3.6
440
17
0.39
ND
ND
ND
ND
ND
ND
SN-54 BOC-D-VLR-ANSNH-C4H9
F.W. = 746.98
(useful for aPC)
KM
kcat
kcat/KM
19
0.055
0.03
42
0.007
0.002
170
1.6
0.09
19
0.055
0.03
ND
ND
ND
3.9
2.1
5.2
ND
ND
ND
ND
ND
ND
SN-59 D-VPR-ANSNH-C4H9 • 2 HCl
F.W. = 703.73
(useful for thrombin and aPC)
KM
kcat
kcat/KM
2.0
110
550
89
0.019
0.002
52
0.76
0.14
160
3.3
0.21
520
92
1.8
54
72
13
110
0.71
0.065
ND
ND
ND

ND = NOT DETERMINED                                

PRICING

INQUIRE ABOUT THESE PRODUCTS

 

©2003. Haematologic Technologies Incorporated. All Rights Reserved.

 

References 
1. Butenas, S., et al., Biochemistry, 31, 5399 (1992). 
2. Lawson, J.H., et al., J. Biol. Chem., 267, 4834 (1992). 
3. Lawson, J.H., et al., Methods in Enzymology, 222, 177 (1993). 
4. Butenas, S., et al., Biochemistry, 32, 6531 (1993). 
5. Butenas, S., et al., J. Biol. Chem., 269, 25838 (1994). 
6. Butenas, S., et al., Anal. Biochem., 225, 231 (1995). 
7. Butenas, S., and Mann, K.G., Biochemistry, 35, 1904 (1996). 
8. Butenas, S., et al., Biochemistry, 36, 2123 (1997). 
9. Butenas, S., et al., J. Biol. Chem., 272, 21527 (1997). 
10. Butenas, S., et al., Thromb. Haemost., 78, 1193 (1997). 
11. Hockin,M.F.,et al.,Arterioscler.Thromb.Vasc.Biol.,in press(1997). 

12. Butenas, S., et al., U.S.A. patent # 5,399,487. 

 
Please inquire about products not listed. 

 

© 2004 Haematologic Technologies, Inc. All Rights ReservedAAA